Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market. Their prices can swing dramatically, driven by the results of FDA clinical trials and the real-world performance of their treatments. In 2020, the biotech sector surged to prominence with the rollout of COVID-19 vaccines. By late 2023 and early 2024, investor interest revived as Big Pharma began spending on acquisitions. However, the momentum slowed, and biotech stocks remained stagnant for months. In the second quarter, biopharma deal activity sharply declined, with only a few M&A deals and IPOs breaking the otherwise quiet period. This slowdown came after a lively first quarter, where pharma finally started deploying its massive cash reserves for acquisitions. On the other hand, despite industry anticipation for a federal interest rate cut, the response has been surprisingly muted. Earlier this September, the Federal Reserve reduced rates by half a percentage point, a larger c
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in AdultsPR Newswire
- Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)PR Newswire
- Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DevicePR Newswire
- Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismPR Newswire
NBIX
Earnings
- 10/30/24 - Beat
NBIX
Sec Filings
- 1/29/25 - Form 4
- 1/27/25 - Form 144
- 1/27/25 - Form 8-K
- NBIX's page on the SEC website